editor@jprims.in
9343055451
e-ISSN: 3049-1681
logo

Journal of Pharmaceutical Research and Integrated Medical Sciences

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

Volume 2, Issue 10 - 2025 (Oct.-2025)

Volume 2 Issue 10 Cover

Issue Details:

Volume 2 Issue 10
Published:Invalid Date

Editorial: Oct.-2025

Welcome to the 2025 issue of Journal of Pharmaceutical Research and Integrated Medical Sciences. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Arpan Kumar Tripathi
Editor-in-Chief
Journal of Pharmaceutical Research and Integrated Medical Sciences

Articles in This Issue

Showing 5 of 5 articles
Research PaperID: jprims-00000176

Review on the role of traditionally used medicinal plant vitex negundo and its current pharmacological aspect.

udayraj waykar, Reshma Balaso Wayal Wayal, Viraj Tatoba Zimal. Zimal, Aditi Bandu Upare. Upare., Pritam G.Bhore. Bhore ., Tushar T.Shelke. Shelke.

The medicinal shrub Vitex negundo Linn. (Nirgundi) is widely utilized in conventional medical systems to treat a variety of ailments such as Ayurveda, Unani, Siddha, and Chinese medicine. The phytochemical profile, historical relevance, and particularly the neuronal pharmacological activities of Vitex  negundo are critically examined in this paper. Flavonoids, terpenoids, alkaloids, and essential oils are highlighted as its bioactive components, which support its therapeutic properties, including anti-inflammatory, antioxidant, neuroprotective, antipyretic, anxiolytic, and analgesic activities. Significant neuronal benefits are highlighted in the literature study, along with preclinical research showing anxiolytic and antinociceptive effects as well as possible uses in neuroinflammatory and neurodegenerative diseases. More thorough Clinical trials are essential for validating the efficacy, safety, and consistent dosing while clarifying molecular pathways, despite encouraging experimental results. Vitex negundo is positioned as a promising candidate for future neurological drug development through the merger of traditional knowledge and modern pharmacological research, but it also emphasizes the necessity of thorough review prior to clinical translation

10,539 views
3,150 downloads

Contributors:

 udayraj waykar
,
 Reshma Balaso Wayal Wayal
,
 Viraj Tatoba Zimal. Zimal
,
 Aditi Bandu Upare. Upare.
,
 Pritam G.Bhore. Bhore .
,
 Tushar T.Shelke. Shelke.
Research PaperID: jprims-00000184

Advances in Thermosensitive Liposomes for Site-Specific Drug Release

Nagaraja Jarugula, Pavan K Chennupati, Rasheed Shaik, M. Sireesha, S. Chandra

Thermosensitive liposomes (TSLs) have emerged as a novel and adaptable platform in nanomedicine, enabling targeted and strategic drug delivery through their thermoresponsive release characteristics. Designed to remain stable at physiological temperatures and to undergo phase transitions at severe hyperthermia (41–43 °C), TSLs can release encapsulated therapeutic agents (e.g., doxorubicin, mitoxantrone, oxaliplatin) in controlled spatial and temporal concentrations to targeted tumors. Preclinical trials demonstrate that TSLs, particularly when combined with localized hyperthermia therapies such as focused ultrasound or radiofrequency heating, significantly enhance intratumoral drug delivery, improve therapeutic efficacy, and diminish systemic toxicity compared to standard chemotherapy. Strategic design changes, including adding lysolipids to lower phase transition temperatures and PEGylation to improve circulation and stem stability, can further improve pharmacokinetics and biocompatibility. A combination of real-time imaging measures gives us a greater chance to follow the liposomes' movement and release medications, which lets us tailor the therapy program to fit each patient. Even though these are good steps forward, there are still problems with standardizing formulations, keeping the temperature very stable throughout hyperthermia, and making preclinical research work for a lot of people in the clinic. Still, ongoing research that focuses on improving the formulation and combining it with other innovative treatments like immunotherapy, gene therapy, and non-invasive thermal procedures is essential to realize the full clinical potential of TSLs. In short, TSLs are a very promising idea for a safe and effective cancer treatment that can be targeted. They also make it possible to improve therapeutic results while keeping off-target side effects to a minimum

Pharmacognostic StandardizationPolyherbal FormulationsQuality ControlChromatographic FingerprintingPhysicochemical ParametersAnimal Models+2 more
11,054 views
3,197 downloads

Contributors:

 Nagaraja Jarugula
,
 Pavan K Chennupati
,
 Rasheed Shaik
,
 M. Sireesha
,
 S. Chandra
Research PaperID: jprims-00000185

Exploring Natural Polymers for the Development of Nifedipine Sustained-Release Matrix System

Jaidev Kumar, Tusar Bajpai

This review will concentrate on the use of natural polymers, such as xanthan gum, tamarind gum, fenugreek gum, and chitosan as part of nifedipine sustained-release matrix systems: the animal-based research will be emphasized. The swelling, gel formation, viscosity, and mucoadhesive characteristics of natural polymers are effective in drug release control to provide a long-lasting and controlled therapeutic plasma concentration. The polymers have potential to increase bioavailability, stability, and safety which have been shown through different formulation strategies such as direct compression, solvent evaporation, and extrusion-spheronization as well as pharmacokinetic assessment in rats and rabbits, in vivo. Although they have these benefits, which include biocompatibility, biodegradability, cost-effectiveness, and sustainability, the issues of batch variability, mechanical constraints, and regulatory barriers are still present. The next generation of such polymer-based systems needs to focus on standardization, mechanistic knowledge, long-term stability and regulatory compatibility to maximize the clinical utility of these future systems.

Preclinical Evaluation.Controlled ReleaseTumor TargetingLysolipidsPegylationSite-Specific Drug Delivery+2 more
10,980 views
3,297 downloads

Contributors:

 Jaidev Kumar
,
 Tusar Bajpai
Research PaperID: jprims-00000187

Formulation of Pediatric Cough Syrup with Reduced Synthetic Preservatives

Somanath Padhan, Soumya Kanta Mishra

The current research is dedicated to the creation of a pediatric cough syrup formula with less synthetic preservatives based on the usage of natural antimicrobial agents. The use of synthetic preservatives in pediatric formulations e.g. sodium benzoate in excess amount leads to concerns about possible toxicity and hypersensitivity. To resolve this, a control syrup that had standard concentration of sodium benzoate (0.1) was used as a control group compared with an optimized formulation that had low concentration (0.03) of sodium benzoate with added honey, clove oil and citric acid. The recipes were tested in terms of physicochemical stability, antimicrobial activity and sensorial properties within 90 days. The challenge testing with the Escherichia coli, Bacillus subtilis, Candida albicans and Aspergillus niger showed successful inhibition of microbial growth by the natural-based preservative system similar to the synthetic preservative. Physicochemical characteristics, such as pH, viscosity, color, odor, and taste were at acceptable pharmacopeial values and this means that they were stable and palatable. Statistical analysis also established there was no significant difference (p less than 0.05) in formulations in microbial reduction and stability performance. The findings indicate that the partial replacement of synthetic preservatives with natural agents is likely to increase the safety of the formulations in question without affecting its quality or effectiveness.

Toxicological safetyPharmacodynamicsAntidiabeticAnti-inflammatoryHepatoprotectiveAntioxidant activity+2 more
11,023 views
3,298 downloads

Contributors:

 Somanath Padhan
,
 Soumya Kanta Mishra
Research PaperID: jprims-00000188

Formulation and Evaluation of Bilayer Matrix tablet of Candesartan and Simvastatin

Akansha Runijha, Deepak Kumar Biswas, Vaminee Madhukar

The present study was undertaken with an aim formulation and evaluation of Bilayer Tablets containing Candesartan and Simvastatin by Direct compression and wet granulation method to formulate a stable, safe and convenience dosage form for the better management of most common cardiovascular disorders blood pressure. The formulations of Bilayer tablets showed good results in case of Candesartan immediate release layer physicochemical parameters and prepared using concentration of super disintegrant sodium starch glycolate for the fast release layer and sustained release layer of simvastatin containing HPMC K100 M and ethyl cellulose for the delay the drug release up to 10-12 hrs. The FTIR analysis indicates that the drug is pure. Pre compression and post compression parameters were found to be within the satisfactory limits and hence suitable to formulate Bilayer tablets. The data obtained from in vitro release study shows that there is a delay in release of drug simvastatin from the sustained layer that is just because of its hydrophobic characteristics of the polymer ethyl cellulose and the mechanism involved in the release of drug is due to erosion of polymer surface from the matrix.

and Bioavailability.Animal ModelsDrug Release KineticsGastric RetentionIn-vitro EvaluationHydrophilic Polymers+2 more
11,367 views
3,392 downloads

Contributors:

 Akansha Runijha
,
 Deepak Kumar Biswas
,
 Vaminee Madhukar